(Alliance News) - Redx Pharma PLC on Monday said it has successfully completed dosing of the first cohort of patients in its ongoing phase 1/2 study with RXC004.
RXC004 is an oral porcupine inhibitor targeting the Wnt signalling pathway. On successful completion of this initial first-phase monotherapy study, RXC004 has the potential to be developed in different cancers and in different treatment settings.
Following a review of the data from this cohort, the Safety Review Committee has recommended that the dose can now be escalated.
The drug discovery and development company said recruitment of the second patient cohort, who will be administered the drug at a higher pre-specified dose of RXC004, has begun.
"We are pleased that the Safety Review Committee has recommended that we can now escalate the dose in the phase 1/2 study of RXC004, our oral porcupine inhibitor, and consequently we have begun enrolment of our second cohort of patients as per protocol," said Chief Executive Lisa Anson.
"We look forward to completing patient enrolment for the phase 1 monotherapy dose-escalation study and to announcing results during 2020," added Anson.
Redx Pharma shares were trading 8.7% higher in London on Monday at 10.05 pence each.
